BioRevolution: Tapping glycogen reserves to build muscle

BioRevolution is preparing to take a first-in-class small molecule into a Phase I basket trial across multiple glycogen storage diseases, betting that mobilizing glycogen in skeletal muscle can drive meaningful gains in strength and function. If the approach translates, the company sees a path into a wide range indications where preserving or rebuilding muscle is the clinical prize, including muscular dystrophy, sarcopenia and potential combination use with GLP-1s in obesity.

BioRevolution LLC CEO Thomas Butler told BioCentury that muscle loss is a core driver of all-cause mortality in older adults. “When looking at the top quartile versus the bottom quartile of muscle mass index, as you age into later adulthood, there is a clinically significant impact on your survival.”...